Recognition of influenza H3N2 variant virus by human neutralizing antibodies

JCI Insight

Volumn 1, Issue 10, 2019, Pages

  Bangaru, Sandhya ^a   Nieusma, Travis ^b   Kose, Nurgun ^c   Thornburg, Natalie J ^c   Finn, Jessica A ^a   Kaplan, Bryan S ^d   King, Hannah G ^c   Singh, Vidisha ^c   Lampley, Rebecca M ^c   Sapparapu, Gopal ^c   Cisneros, Alberto ^a   Edwards, Kathryn M ^c   Slaughter, James C ^c   Edupuganti, Srilatha ^e   Lai, Lilin ^e   Richt, Juergen A ^f   Webby, Richard J ^d   Ward, Andrew B ^b   Crowe, James E ^a,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f KANSAS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY H3V 104; MONOCLONAL ANTIBODY H3V 126; MONOCLONAL ANTIBODY H3V 141; MONOCLONAL ANTIBODY H3V 71; MONOCLONAL ANTIBODY H3V 81; MONOCLONAL ANTIBODY H3V 98; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTIGENIC VARIATION; ARTICLE; BINDING COMPETITION; CONTROLLED STUDY; DNA MODIFICATION; DRUG BINDING SITE; DRUG CROSS REACTIVITY; DRUG ISOLATION; DRUG POTENCY; DRUG SPECIFICITY; DRUG STRUCTURE; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FEMALE; GENETIC POLYMORPHISM; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN CELL; IC50; IMMUNOPHENOTYPING; IMMUNOPROPHYLAXIS; INFLUENZA A; INFLUENZA A VIRUS (A HIROSHIMA 52 2005(H3N2)); INFLUENZA A VIRUS (A MINNESOTA 11 2010(H3N2)); INFLUENZA A VIRUS (A NEW YORK 55 2004(H3N2)); INFLUENZA A VIRUS (A VICTORIA 361 2011(H3N2)); INFLUENZA A VIRUS (A WISCONSIN 67 2005(H3N2)); INFLUENZA A VIRUS (H3N2); INFLUENZA VACCINATION; MOUSE; NONHUMAN; NORMAL HUMAN; PIG; POPULATION GENETICS; PROTEIN STRUCTURE; SITE DIRECTED MUTAGENESIS; VIRUS NEUTRALIZATION; VIRUS STRAIN;

EID: 85019501066     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.86673     Document Type: Article

References (34)

1. World Health Organization. Influenza (Seasonal). WHO Web site. http://www.who.int/mediacentre/factsheets/fs211/en/. Accessed June 13, 2016.
2. Dreyfus C, et al. Structure of a classical broadly neutralizing stem antibody in complex with a pandemic H2 influenza virus hemagglutinin. J Virol. 2013;87(12):7149–7154.
3. Tong S, et al. New world bats harbor diverse influenza A viruses. PLoS Pathog. 2013;9(10):e1003657.
4. Suzuki Y, et al. Sialic acid species as a determinant of the host range of influenza A viruses. J Virol. 2000;74(24):11825–11831.
5. Rogers GN, Paulson JC. Receptor determinants of human and animal influenza virus isolates: Differences in receptor specificity of the H3 hemagglutinin based on species of origin. Virology. 1983;127(2):361–373.
6. Ito T, et al. Molecular basis for the generation in pigs of influenza A viruses with pandemic potential. J Virol. 1998;72(9):7367–7373.
7. Connor RJ, et al. Receptor specificity in human, avian, and equine H2 and H3 influenza virus isolates. Virology. 1994;205(1):17–23.
8. Brown IH. The pig as an intermediate host for influenza A viruses between birds and humans. Int Congr Ser. 2001;1219:173–178.
9. Myers KP, et al. Cases of swine influenza in humans: a review of the literature. Clin Infect Dis. 2007;44(8):1084–1088.
10. Smith GJD, et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature. 2009;459(7250):1122–1125.
11. Centers for Disease Control Prevention. Update: Influenza A (H3N2)v transmission guidelines — five states, 2011. MMWR Morb Mortal Wkly Rep. 2012;60(51–52):1741–1744.
12. Finelli L, Swerdlow DL. The emergence of influenza A (H3N2)v virus: what we learned from the first wave. Clin Infect Dis. 2013;57(suppl 1):S1–S3.
13. Lindstrom S, et al. Human infections with novel reassortant influenza A(H3N2)v viruses, United States, 2011. Emerging Infect Dis. 2012;18(5):834–837.
14. Skowronski DM, et al. Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v). J Infect Dis. 2012;206(12):1852–1861.
15. Centers for Disease Control Prevention. Antibodies cross-reactive to influenza A (H3N2) variant virus impact of 2010-11 seasonal influenza vaccine on cross-reactive antibodies-United States. MMWR Morb Mortal Wkly Rep. 2012;61(14):237–241.
16. Waalen K, et al. Age-dependent prevalence of antibodies cross-reactive to the influenza A (H3N2) variant virus in sera collected in Norway in 2011. Euro Surveill. 2012;17(19): 20170.
17. Zhou NN, et al. Emergence of H3N2 reassortant influenza A viruses in North American pigs. Vet Microbiol. 2000;74(1–2):47–58.
18. Zhou NN, et al. Genetic reassortment of avian, swine, and human influenza A viruses in American pigs. J Virol. 1999;73(10):8851–8856.
19. Webby RJ, et al. Evolution of swine H3N2 influenza viruses in the United States. J Virol. 2000;74(18):8243–8251.
20. Keitel WA, et al. Safety and immunogenicity of a subvirion monovalent unadjuvanted inactivated influenza A/H3N2 variant (H3N2v) vaccine in healthy persons ≥ 18 years old. J Infect Dis. 2015;212(4):552–561.
21. Koel BF, et al. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science. 2013;342(6161):976–979.
22. Choi MJ, et al. Live animal markets in Minnesota: A potential source for emergence of novel influenza A viruses and interspecies Transmission. Clin Infect Dis. 2015;61(9):1355–1362.
23. Manicassamy B, et al. Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathog. 2010;6(1):e1000745.
24. Nelson MI, et al. Multiple reassortment events in the evolutionary history of H1N1 influenza A virus since 1918. PLoS Pathog. 2008;4(2):e1000012.
25. Vincent AL, Ma W, Lager KM, Janke BH, Richt JA. Swine influenza viruses a North American perspective. Adv Virus Res. 2008;72:127–154.
26. Lina B, et al. S-OtrH3N2 viruses: use of sequence data for description of the molecular characteristics of the viruses and their relatedness to previously circulating H3N2 human viruses. Euro Surveill. 2011;16(50):20039.
27. Smith SA, et al. Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. J Virol. 2012;86(5):2665–2675.
28. Thornburg NJ, et al. Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza viruses. J Clin Invest. 2013;123(10):4405–4409.
29. Suloway C, et al. Automated molecular microscopy: The new Leginon system. J Struct Biol. 2005;151(1):41–60.
30. Voss NR, et al. DoG Picker and TiltPicker: Software tools to facilitate particle selection in single particle electron microscopy. J Struct Biol. 2009;166(2):205–213.
31. Hohn M, et al. SPARX, a new environment for Cryo-EM image processing. J Struct Biol. 2007;157(1):47–55.
32. van Heel M, et al. A new generation of the IMAGIC image processing system. J Struct Biol. 1996;116(1):17–24.
33. Tang G, et al. EMAN2: An extensible image processing suite for electron microscopy. J Struct Biol. 2007;157(1):38–46.
34. Ludtke SJ, et al. EMAN: Semiautomated software for high-resolution single-particle reconstructions. J Struct Biol. 1999;128(1):82–97.